Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kura Oncology, Inc. - Common Stock (NQ:KURA)

6.795 +0.225 (+3.42%)
Streaming Delayed Price Updated: 11:40 AM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kura Oncology, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Why Kura Oncology Stock Is Moving Higher Tuesday Morning
Kura Oncology Inc (NASDAQ: KURA) shares are trading higher Tuesday after the company announced the FDA clearance of its Inve 
Via Benzinga
Cramer Is Holding This Biotech Stock
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended holding Biomarin Pharmaceutical Inc (NASDAQ: BMRN). 
Via Benzinga
Kura Oncology Shares Fall After Updated Ziftomenib Data At ASH Meeting
Via Benzinga
Kura Oncology Reports Preliminary Proof Of Mechanism Data From Early-Stage In Head & Neck Cancer
Via Benzinga
Read Why Did Credit Suisse Raise Price Target On Kura Oncology
Via Benzinga
RH, HUYA, Bilibili And Some Other Big Stocks Moving Lower On Monday
U.S. stocks traded higher, with the Dow Jones jumping more than 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Preview: Kura Oncology's Earnings
Kura Oncology (NASDAQ:KURA) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Kura Oncology... 
Via Benzinga
Kura Oncology Stock Shows Improved Relative Strength; Still Shy Of Benchmark
In a welcome move, Kura Oncology stock saw its Relative Strength Rating improve from 69 to 75 on Wednesday. 
Via Investor's Business Daily
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
Micron, Charles River Laboratories And Some Other Big Stocks Moving Higher On Friday
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining more than 80 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Kura Oncology Stock Joins Rank Of Stocks With RS Ratings Over 90
On Monday, Kura Oncology stock had its Relative Strength (RS) Rating upgraded to 91, up from 85 a day earlier. 
Via Investor's Business Daily
7 Cheap Biotech Stocks to Buy Now
These cheap biotech stocks to buy offer investors a way to get ready for the inevitable comeback in the biopharmaceutical sector. 
Via InvestorPlace
Earnings Preview: Kura Oncology
Kura Oncology (NASDAQ:KURA) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that Kura... 
Via Benzinga
Kura Oncology Stock Scores Rising Relative Strength
On Thursday, Kura Oncology stock had its Relative Strength (RS) Rating stock upgraded to 93 from 81 a day earlier. 
Via Investor's Business Daily
PreMarket Prep: Looking For Biotech Bargains With This Wedbush Analyst
Biotechnology is one sector that peaked ahead of the S&P 500 index. While the S&P 500 index did not peak until January, the SPDR Biotech (NYSE: XBI) peaked in February 2021 and is now 60% lower than... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022
Upgrades 
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal 
Via Benzinga
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion. 
Via Benzinga
Kura Oncology, Inc. (NASDAQ:KURA) Investor Notice: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 03/04/2022 -- Certain directors of Kura Oncology, Inc are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Kura Oncology: Q4 Earnings Insights
Kura Oncology (NASDAQ:KURA) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2022
Upgrades For Blue Bird Corp (NASDAQ:BLBD), Roth Capital upgraded the previous rating of Neutral to Buy. Blue Bird earned $0.07 in the first quarter, compared to $0.00 in the year-... 
Via Benzinga
The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kura Announces Lifting Of Clinical Hold On Phase 1 Blood Cancer Study Kura... 
Via Benzinga
Groundbreaking Clinical Trials Accelerating New Treatment Options for Pancreatic Cancer
Palm Beach, FL – February 2, 2022 – FinancialNewsMedia.com News Commentary – In the battle against pancreatic cancer, new and innovative clinical trials have become extremely critical. These trials... 
Via FinancialNewsMedia
FDA Lifts Partial Hold On Kura Oncology's Early-Stage Leukemia Trial
The FDA has lifted the partial clinical hold on Kura Oncology Inc (NASDAQ: KURA) KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory... 
Via Benzinga
NASDAQ:KURA Investor Notice: Investigation over Possible Securities Laws Violations by Kura Oncology, Inc.
San Diego, CA -- (SBWIRE) -- 12/09/2021 -- Kura Oncology, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Exposures Product Safety
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.